http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2687968-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baee372c55802742f9582e25c15ff11a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57442 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2014-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed7094a8175c1dbb6adb1f2a5f458bf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_786aaf98f25d50973771e02f900e1e9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9e7d82862b4302def7ad97996a23e3e |
| publicationDate | 2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2687968-T3 |
| titleOfInvention | Biomarkers to predict and evaluate the reactivity of subjects with endometrial cancer to compounds with lenvatinib |
| abstract | A method for predicting the response of a human subject suffering from, is presumed to be suffering from or at risk of developing endometrial cancer, to a treatment comprising lenvatinib or a pharmaceutically acceptable salt thereof, the method comprises: testing a biological sample obtained from the human subject and determine that the concentration of the Angiopoietin 2 (Ang2) protein in the biological sample is low, compared to a control; and identifying that the human subject that has a low concentration of the Ang2 protein in the biological sample is likely to respond to treatment comprising lenvatinib or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 777.